Biography
James is an experienced healthcare executive with over 20 years experience across a variety of healthcare segments. Before joining Enterprises, James was the Chief Strategic Officer and General Counsel of ByHeart, Inc., an infant formula company, where he led FDA strategy, managed legal affairs and led the acquisition and establishment of the company’s manufacturing facility. Prior to ByHeart, James worked in the pharmaceutical sector for over 15 years holding a variety of positions at Fresenius Kabi, including SVP of the portfolio and marketing strategy unit, and then at Amneal where he oversaw corporate development and procurement groups. Before his tenure at Fresenius and Amneal, James spent 10 years practicing law with a focus on IP, Hatch Waxman litigation and FDA matters. He earned a B.S. from Notre Dame, a J.D. from the Pennsylvania State University, and an M.S. from Drexel. He is a registered U.S. Patent Attorney and maintains a Pennsylvania law license.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.
Sessions: